Metacrine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapies for patients with liver and gastrointestinal (GI) diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The company went IPO on 2020-09-16. The firm is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The Company’s advanced program targets the farnesoid X receptor (FXR), which is central to modulating GI and liver diseases. The Company’s pipeline includes MET642 and hydroxysteroid dehydrogenase 17B13 (HSD17B13 or HSD). MET642 is used for the treatment of inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn’s disease. HSD17B13 is used for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The firm is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). The firm has built a proprietary library of approximately 2,500 FXR compounds.